Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

In Memoriam: Professor Joerg Ritter, MD, PhD (1944-2019).

Groll AH.

Mycoses. 2019 Oct;62(10):979. doi: 10.1111/myc.12976. Epub 2019 Sep 11. No abstract available.

PMID:
31506982
2.

Galactomannan and PCR in the Central Nervous System to Detect Invasive Mold Disease - A Retrospective Analysis in Immunocompromised Children.

Lehrnbecher T, Rath PM, Attarbaschi A, Cario G, Döring M, Moser O, Mücke U, Poyer F, Rieken S, Temme C, Voigt S, Groll AH, Lauten M.

Sci Rep. 2019 Sep 10;9(1):12950. doi: 10.1038/s41598-019-49426-0.

3.

Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents.

Tragiannidis A, Herbrüggen H, Ahlmann M, Vasileiou E, Gastine S, Thorer H, Fröhlich B, Müller C, Groll AH.

J Antimicrob Chemother. 2019 Aug 27. pii: dkz359. doi: 10.1093/jac/dkz359. [Epub ahead of print]

PMID:
31504563
4.

Epidemiology and management burden of invasive fungal infections after autologous hematopoietic stem cell transplantation: 10-year experience at a European Pediatric Cancer Center.

Linke C, Tragiannidis A, Ahlmann M, Fröhlich B, Wältermann M, Burkhardt B, Rossig C, Groll AH.

Mycoses. 2019 Oct;62(10):954-960. doi: 10.1111/myc.12968. Epub 2019 Aug 18.

PMID:
31332851
5.

Preclinical Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antifungal Activity of Liposomal Amphotericin B.

Adler-Moore J, Lewis RE, Brüggemann RJM, Rijnders BJA, Groll AH, Walsh TJ.

Clin Infect Dis. 2019 May 2;68(Supplement_4):S244-S259. doi: 10.1093/cid/ciz064.

6.

Clinical Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of Liposomal Amphotericin B.

Groll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM.

Clin Infect Dis. 2019 May 2;68(Supplement_4):S260-S274. doi: 10.1093/cid/ciz076.

7.

Pre-emptive versus empirical antifungal therapy in immunocompromised children.

Lehrnbecher T, Groll AH.

Lancet Child Adolesc Health. 2019 Aug;3(8):518-520. doi: 10.1016/S2352-4642(19)30191-9. Epub 2019 Jun 13. No abstract available.

PMID:
31204310
8.

ESCMID-ECMM guideline: diagnosis and management of invasive aspergillosis in neonates and children.

Warris A, Lehrnbecher T, Roilides E, Castagnola E, Brüggemann RJM, Groll AH.

Clin Microbiol Infect. 2019 Sep;25(9):1096-1113. doi: 10.1016/j.cmi.2019.05.019. Epub 2019 May 31.

PMID:
31158517
9.

Extended Dosing Regimens for Fungal Prophylaxis.

Lehrnbecher T, Bochennek K, Klingebiel T, Gastine S, Hempel G, Groll AH.

Clin Microbiol Rev. 2019 May 15;32(3). pii: e00010-19. doi: 10.1128/CMR.00010-19. Print 2019 Jun 19. Review.

PMID:
31092507
10.

Invasive mold disease of the central nervous system in children and adolescents with cancer or undergoing hematopoietic stem cell transplantation: Analysis of 29 contemporary patients.

Lauten M, Attarbaschi A, Cario G, Döring M, Moser O, Mücke U, Poyer F, Rieken S, Temme C, Voigt S, Lehrnbecher T, Groll AH.

Pediatr Blood Cancer. 2019 Aug;66(8):e27806. doi: 10.1002/pbc.27806. Epub 2019 May 7.

PMID:
31066209
11.

Incidence and Outcome of Invasive Fungal Diseases in Children With Hematological Malignancies and/or Allogeneic Hematopoietic Stem Cell Transplantation: Results of a Prospective Multicenter Study.

Lehrnbecher T, Schöning S, Poyer F, Georg J, Becker A, Gordon K, Attarbaschi A, Groll AH.

Front Microbiol. 2019 Apr 16;10:681. doi: 10.3389/fmicb.2019.00681. eCollection 2019.

12.

Cytomegalovirus retinitis in children and adolescents with acute leukemia following allogeneic hematopoietic stem cell transplantation.

Zöllner SK, Herbrüggen H, Kolve H, Mihailovic N, Schubert F, Reicherts C, Rössig C, Groll AH.

Transpl Infect Dis. 2019 Apr 10:e13089. doi: 10.1111/tid.13089. [Epub ahead of print]

PMID:
30972869
13.

A non-randomized trial to assess the safety, tolerability, and pharmacokinetics of posaconazole oral suspension in immunocompromised children with neutropenia.

Arrieta AC, Sung L, Bradley JS, Zwaan CM, Gates D, Waskin H, Carmelitano P, Groll AH, Lehrnbecher T, Mangin E, Joshi A, Kartsonis NA, Walsh TJ, Paschke A.

PLoS One. 2019 Mar 26;14(3):e0212837. doi: 10.1371/journal.pone.0212837. eCollection 2019.

14.

Disseminated Bartonella henselae disease mimicking Langerhans' cell histiocytosis.

Apsemidou A, Rauwolf K, Tragiannidis A, Brentrup A, Schiborr M, Becker K, Ahlmann M, Groll AH.

Pediatr Blood Cancer. 2019 Apr;66(4):e27573. doi: 10.1002/pbc.27573. Epub 2018 Dec 17.

PMID:
30556266
15.

Durable control of hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation.

Rauwolf K, Herbrüggen H, Zöllner S, Thorer H, Makarova O, Kaiser T, Pettke A, Rossig C, Burkhardt B, Groll AH.

J Viral Hepat. 2019 Apr;26(4):454-458. doi: 10.1111/jvh.13046. Epub 2018 Dec 28.

PMID:
30516856
16.

Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.

Kaindl T, Andes D, Engelhardt M, Saulay M, Larger P, Groll AH.

J Antimicrob Chemother. 2019 Mar 1;74(3):761-767. doi: 10.1093/jac/dky463.

17.

Toxoplasmosis in Transplant Recipients, Europe, 2010-2014.

Robert-Gangneux F, Meroni V, Dupont D, Botterel F, Garcia JMA, Brenier-Pinchart MP, Accoceberry I, Akan H, Abbate I, Boggian K, Bruschi F, Carratalà J, David M, Drgona L, Djurković-Djaković O, Farinas MC, Genco F, Gkrania-Klotsas E, Groll AH, Guy E, Hirzel C, Khanna N, Kurt Ö, Junie LM, Lazzarotto T, Len O, Mueller NJ, Munoz P, Pana ZD, Roilides E, Stajner T, van Delden C, Villena I, Pelloux H, Manuel O.

Emerg Infect Dis. 2018 Aug;24(8):1497-1504. doi: 10.3201/eid2408.180045.

18.

Front-line imatinib treatment in children and adolescents with chronic myeloid leukemia: results from a phase III trial.

Suttorp M, Schulze P, Glauche I, Göhring G, von Neuhoff N, Metzler M, Sedlacek P, de Bont ESJM, Balduzzi A, Lausen B, Aleinikova O, Sufliarska S, Henze G, Strauss G, Eggert A, Kremens B, Groll AH, Berthold F, Klein C, Groß-Wieltsch U, Sykora KW, Borkhardt A, Kulozik AE, Schrappe M, Nowasz C, Krumbholz M, Tauer JT, Claviez A, Harbott J, Kreipe HH, Schlegelberger B, Thiede C.

Leukemia. 2018 Jul;32(7):1657-1669. doi: 10.1038/s41375-018-0179-9. Epub 2018 Jun 20.

PMID:
29925908
19.

Diagnostic Approaches for Invasive Aspergillosis-Specific Considerations in the Pediatric Population.

Lehrnbecher T, Hassler A, Groll AH, Bochennek K.

Front Microbiol. 2018 Mar 26;9:518. doi: 10.3389/fmicb.2018.00518. eCollection 2018. Review.

20.

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline.

Ullmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux JP, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA.

Clin Microbiol Infect. 2018 May;24 Suppl 1:e1-e38. doi: 10.1016/j.cmi.2018.01.002. Epub 2018 Mar 12.

21.

First description of a local Coprinopsis cinerea skin and soft tissue infection.

Correa-Martinez C, Brentrup A, Hess K, Becker K, Groll AH, Schaumburg F.

New Microbes New Infect. 2017 Dec 5;21:102-104. doi: 10.1016/j.nmni.2017.11.008. eCollection 2018 Jan.

22.

Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children.

Gastine S, Lehrnbecher T, Müller C, Farowski F, Bader P, Ullmann-Moskovits J, Cornely OA, Groll AH, Hempel G.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01194-17. doi: 10.1128/AAC.01194-17. Print 2018 Jan.

23.

Diagnostic Imaging and Invasive Fungal Diseases in Children.

Katragkou A, Fisher BT, Groll AH, Roilides E, Walsh TJ.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(suppl_1):S22-S31. doi: 10.1093/jpids/pix055. Review.

PMID:
28927203
24.

Epidemiology of Invasive Fungal Disease in Children.

Pana ZD, Roilides E, Warris A, Groll AH, Zaoutis T.

J Pediatric Infect Dis Soc. 2017 Sep 1;6(suppl_1):S3-S11. doi: 10.1093/jpids/pix046. Review.

25.

Vaccination against influenza at a European pediatric cancer center: immunization rates and attitudes among staff, patients, and their families.

Pettke A, Jocham S, Wiener A, Löcken A, Groenefeld J, Ahlmann M, Groll AH.

Support Care Cancer. 2017 Dec;25(12):3815-3822. doi: 10.1007/s00520-017-3813-6. Epub 2017 Jul 21.

PMID:
28733696
26.

Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4.

Groll AH, Townsend R, Desai A, Azie N, Jones M, Engelhardt M, Schmitt-Hoffman AH, Brüggemann RJM.

Transpl Infect Dis. 2017 Oct;19(5). doi: 10.1111/tid.12751. Epub 2017 Sep 28. Review.

PMID:
28722255
27.

Control of Multidrug-Resistant Pseudomonas aeruginosa in Allogeneic Hematopoietic Stem Cell Transplant Recipients by a Novel Bundle Including Remodeling of Sanitary and Water Supply Systems.

Kossow A, Kampmeier S, Willems S, Berdel WE, Groll AH, Burckhardt B, Rossig C, Groth C, Idelevich EA, Kipp F, Mellmann A, Stelljes M.

Clin Infect Dis. 2017 Sep 15;65(6):935-942. doi: 10.1093/cid/cix465.

PMID:
28520856
28.

Guideline for the Management of Fever and Neutropenia in Children With Cancer and Hematopoietic Stem-Cell Transplantation Recipients: 2017 Update.

Lehrnbecher T, Robinson P, Fisher B, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L.

J Clin Oncol. 2017 Jun 20;35(18):2082-2094. doi: 10.1200/JCO.2016.71.7017. Epub 2017 May 1. Review.

PMID:
28459614
29.

Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.

Kyriakidis I, Tragiannidis A, Zündorf I, Groll AH.

Mycoses. 2017 Aug;60(8):493-507. doi: 10.1111/myc.12621. Epub 2017 Apr 26. Review.

PMID:
28444889
30.

Progressive histoplasmosis with hemophagocytic lymphohistiocytosis and epithelioid cell granulomatosis: A case report and review of the literature.

Schulze AB, Heptner B, Kessler T, Baumgarten B, Stoica V, Mohr M, Wiewrodt R, Warneke VS, Hartmann W, Wüllenweber J, Schülke C, Schäfers M, Wilmes D, Becker K, Schmidt LH, Groll AH, Berdel WE.

Eur J Haematol. 2017 Jul;99(1):91-100. doi: 10.1111/ejh.12886. Epub 2017 May 11. Review.

PMID:
28349614
31.

Serial assessment of pulmonary lesion volume by computed tomography allows survival prediction in invasive pulmonary aspergillosis.

Vehreschild JJ, Heussel CP, Groll AH, Vehreschild MJGT, Silling G, Würthwein G, Brecht M, Cornely OA.

Eur Radiol. 2017 Aug;27(8):3275-3282. doi: 10.1007/s00330-016-4717-4. Epub 2017 Jan 12.

PMID:
28083695
32.

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.

Tissot F, Agrawal S, Pagano L, Petrikkos G, Groll AH, Skiada A, Lass-Flörl C, Calandra T, Viscoli C, Herbrecht R.

Haematologica. 2017 Mar;102(3):433-444. doi: 10.3324/haematol.2016.152900. Epub 2016 Dec 23.

33.

Clinical hepatotoxicity associated with antifungal agents.

Kyriakidis I, Tragiannidis A, Munchen S, Groll AH.

Expert Opin Drug Saf. 2017 Feb;16(2):149-165. doi: 10.1080/14740338.2017.1270264. Epub 2016 Dec 16. Review.

PMID:
27927037
34.

Safety, Tolerability, and Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Pediatric Patients.

Seibel NL, Shad AT, Bekersky I, Groll AH, Gonzalez C, Wood LV, Jarosinski P, Buell D, Hope WW, Walsh TJ.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01477-16. doi: 10.1128/AAC.01477-16. Print 2017 Feb.

35.

Current Algorithms in Fungal Diagnosis in the Immunocompromised Host.

Lehrnbecher T, Becker K, Groll AH.

Methods Mol Biol. 2017;1508:67-84.

PMID:
27837498
36.

Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries.

Pana ZD, Seidel D, Skiada A, Groll AH, Petrikkos G, Cornely OA, Roilides E; Collaborators of Zygomyco.net and/or FungiScope™ Registries*.

BMC Infect Dis. 2016 Nov 10;16(1):667.

37.

Galactomannan, β-D-Glucan, and Polymerase Chain Reaction-Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.

Lehrnbecher T, Robinson PD, Fisher BT, Castagnola E, Groll AH, Steinbach WJ, Zaoutis TE, Negeri ZF, Beyene J, Phillips B, Sung L.

Clin Infect Dis. 2016 Nov 15;63(10):1340-1348. Epub 2016 Aug 27. Review.

38.

Invasive fungal infections in pediatric patients treated with tumor necrosis alpha (TNF-α) inhibitors.

Tragiannidis A, Kyriakidis I, Zündorf I, Groll AH.

Mycoses. 2017 Apr;60(4):222-229. doi: 10.1111/myc.12576. Epub 2016 Oct 21. Review.

PMID:
27766695
39.

Population Pharmacokinetics of Liposomal Amphotericin B in Immunocompromised Children.

Lestner JM, Groll AH, Aljayyoussi G, Seibel NL, Shad A, Gonzalez C, Wood LV, Jarosinski PF, Walsh TJ, Hope WW.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7340-7346. doi: 10.1128/AAC.01427-16. Print 2016 Dec.

40.

Pharmacokinetic Assessment of Drug-Drug Interactions of Isavuconazole With the Immunosuppressants Cyclosporine, Mycophenolic Acid, Prednisolone, Sirolimus, and Tacrolimus in Healthy Adults.

Groll AH, Desai A, Han D, Howieson C, Kato K, Akhtar S, Kowalski D, Lademacher C, Lewis W, Pearlman H, Mandarino D, Yamazaki T, Townsend R.

Clin Pharmacol Drug Dev. 2017 Jan;6(1):76-85. doi: 10.1002/cpdd.284. Epub 2016 Jul 25.

41.

Utility of voriconazole therapeutic drug monitoring: a meta-analysis.

Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, Husain S.

J Antimicrob Chemother. 2016 Jul;71(7):1786-99. doi: 10.1093/jac/dkw099. Epub 2016 May 10.

PMID:
27165788
42.

Biomarker-based diagnostic work-up of invasive pulmonary aspergillosis in immunocompromised paediatric patients--is Aspergillus PCR appropriate?

Buchheidt D, Reinwald M, Spiess B, Boch T, Hofmann WK, Groll AH, Lehrnbecher T; Working Group “Infections in Hematology and Oncology”, German Paul-Ehrlich-Society.

Mycoses. 2016 Feb;59(2):67-74. doi: 10.1111/myc.12443. Epub 2015 Dec 14. Review.

PMID:
26756571
43.

A Prospective, International Cohort Study of Invasive Mold Infections in Children.

Wattier RL, Dvorak CC, Hoffman JA, Brozovich AA, Bin-Hussain I, Groll AH, Castagnola E, Knapp KM, Zaoutis TE, Gustafsson B, Sung L, Berman D, Halasa NB, Abzug MJ, Velegraki A, Sharma TS, Fisher BT, Steinbach WJ.

J Pediatric Infect Dis Soc. 2015 Dec;4(4):313-22. doi: 10.1093/jpids/piu074. Epub 2014 Jul 16.

44.

Estimated burden of fungal infections in Germany.

Ruhnke M, Groll AH, Mayser P, Ullmann AJ, Mendling W, Hof H, Denning DW; University of Manchester in association with the LIFE program.

Mycoses. 2015 Oct;58 Suppl 5:22-8. doi: 10.1111/myc.12392.

PMID:
26449503
45.

International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.

Verweij PE, Ananda-Rajah M, Andes D, Arendrup MC, Brüggemann RJ, Chowdhary A, Cornely OA, Denning DW, Groll AH, Izumikawa K, Kullberg BJ, Lagrou K, Maertens J, Meis JF, Newton P, Page I, Seyedmousavi S, Sheppard DC, Viscoli C, Warris A, Donnelly JP.

Drug Resist Updat. 2015 Jul-Aug;21-22:30-40. doi: 10.1016/j.drup.2015.08.001. Epub 2015 Aug 7.

46.

Detection of SMARCB1 loss in ascites cells in the diagnosis of an abdominal rhabdoid tumor.

Kerl K, Oyen F, Leuschner I, Schneppenheim R, Nagel I, Siebert R, Groll AH, Hartmann W, Barth PJ, Bartelheim K, Seringer A, Wardelmann E, Frühwald MC.

Pediatr Blood Cancer. 2015 May;62(5):897-900. doi: 10.1002/pbc.25412. Epub 2015 Feb 7.

PMID:
25663425
47.

Cerebral toxoplasmosis in an adolescent post allogeneic hematopoietic stem cell transplantation: successful outcome by antiprotozoal chemotherapy and CD4+ T-lymphocyte recovery.

Kerl K, Ehlert K, Brentrup A, Schiborr M, Keyvani K, Becker K, Rossig C, Groll AH.

Transpl Infect Dis. 2015 Feb;17(1):119-24. doi: 10.1111/tid.12344. Epub 2015 Jan 12.

PMID:
25581774
48.

Micafungin twice weekly as antifungal prophylaxis in paediatric patients at high risk for invasive fungal disease.

Bochennek K, Balan A, Müller-Scholden L, Becker M, Farowski F, Müller C, Groll AH, Lehrnbecher T.

J Antimicrob Chemother. 2015 May;70(5):1527-30. doi: 10.1093/jac/dku544. Epub 2015 Jan 5.

PMID:
25564562
49.

Physiology-based pharmacokinetics of caspofungin for adults and paediatrics.

Stader F, Wuerthwein G, Groll AH, Vehreschild JJ, Cornely OA, Hempel G.

Pharm Res. 2015 Jun;32(6):2029-37. doi: 10.1007/s11095-014-1595-9. Epub 2014 Dec 19.

PMID:
25522788
50.

Invasive candidiasis and candidaemia in neonates and children: update on current guidelines.

Tragiannidis A, Tsoulas C, Groll AH.

Mycoses. 2015 Jan;58(1):10-21. doi: 10.1111/myc.12268. Epub 2014 Oct 28. Review.

PMID:
25350572

Supplemental Content

Loading ...
Support Center